PHIO PHARMACEUTICALS CORP. Deferred Tax Assets, Tax Deferred Expense, Other
PHIO PHARMACEUTICALS CORP. (PHIO) had Deferred Tax Assets, Tax Deferred Expense, Other of $2.00 thousand as of 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Income Taxes
us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther · last filed 2020-03-26
- 2019-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $2.00K.
- 2018-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $0.00.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Other |
|---|---|
| 2019-12-31 | $2.00K 10-K · filed 2020-03-26 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |